Chardan Capital Reiterates Buy Rating for EyePoint, Inc.
Chardan Capital has reiterated its buy rating on EyePoint, Inc. with a price target of $65, a 354.55% upside from the current price.
Key Points
- Chardan Capital reiterated its buy rating for EyePoint, Inc. (EYPT) on July 1, 2026, with a price target of $65.
- Chardan Capital's $65 price target implies 354.55% upside from EyePoint, Inc.'s ($EYPT) current $14.30 share price.
- EyePoint, Inc. shares traded at $14.30 on Wednesday, with a market cap of around $1.2 billion and a 52-week range between $8.96 and $19.11.
- Institutional investors like Suvretta Capital and BlackRock have adjusted their positions in EyePoint, Inc., reflecting varied levels of confidence.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Chardan Capital has reiterated its buy rating on EyePoint, Inc. (NasdaqGM: EYPT), maintaining a price target of $65. This update was issued on July 1, 2026, by analyst Andreas Argyrides. Shares of EyePoint traded at approximately $14.30 on Wednesday.
Other Institutional Activity in EyePoint, Inc.
Several institutional investors have made changes to their holdings in EyePoint, Inc. Suvretta Capital Management increased its stake by 468,690 shares, ending with 8,296,375 shares valued at about $106.9 million. BlackRock, Inc. also added 389,465 shares, bringing its total to 7,177,337 shares worth roughly $92.5 million. In contrast, Federated Hermes, Inc. trimmed its holdings by 347,844 shares, now holding 5,669,589 shares valued at $73.1 million. Meanwhile, Janus Henderson Group PLC made a notable increase, adding 663,439 shares to reach a total of 3,601,168 shares valued at $46.4 million.
EyePoint, Inc. Stock Up 219.2%
On Wednesday, shares of EyePoint, Inc. traded near $14.30. The company, with a market capitalization of around $1.2 billion, operates in the biotechnology sector. EyePoint's stock has seen a 52-week low of $8.96 and a high of $19.11. Its 50-day moving average stands at $13.22, while the 200-day moving average is $14.12. The company has a current ratio of 6.66 and a quick ratio of 5.97, indicating strong liquidity.
$EYPT price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
EyePoint, Inc. reported revenue of $7.6 million, with a modest growth rate of 1.6%. Despite this, the company is not yet profitable, reflected in its negative return on equity of -102.71% and net margin of 0%. The next earnings release is anticipated on August 5, 2026.
Insider Buying and Selling at EyePoint, Inc.
EyePoint's Chief Financial Officer, George Elston, was active on May 25, 2026, selling 3,627 shares at an average price of $12.93. On the same day, he also bought and sold 7,500 shares without a specified price. Chief Medical Officer Ramiro Ribeiro bought 2,437 shares on April 17, 2026, at $8.26 and later sold the same amount at $15.00 under a planned transaction.
Analysts Set New Price Targets
On July 1, 2026, Chardan Capital maintained its buy rating on EyePoint, Inc. with a price target of $65. Previously, on June 24, 2026, Guggenheim reiterated a buy rating with a slightly higher target of $68. RBC Capital and Citigroup have also maintained buy ratings in recent months, with targets of $37 and $35, respectively. The consensus among 12 analysts is a strong buy, with an average target price of $37.
About EyePoint, Inc.
EyePoint, Inc., headquartered in Watertown, Massachusetts, focuses on developing treatments for serious retinal diseases. The company's lead product, DURAVYU, is in Phase 3 trials for conditions like wet age-related macular degeneration and diabetic macular edema. EyePoint utilizes its Durasert E technology for sustained intraocular drug delivery. Dr. Jay S. Duker serves as the CEO, leading a team of 214 employees.
Bottom Line
EyePoint, Inc. continues to attract attention from analysts and institutional investors. Chardan Capital's reiterated buy rating and $65 price target reflect confidence in the company's potential. Investors should note that 13F filings and analyst ratings are backward-looking indicators that provide insights into institutional sentiment and expectations.
Get EyePoint, Inc. alerts
New 13F filings, insider trades, and analyst moves on $EYPT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.